Terms: = Breast cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
3364 results:
1. Nuclear Softness Promotes the Metastatic Potential of Large-Nucleated Colorectal cancer Cells via the ErbB4-akt1-Lamin A/C Signaling Pathway.
Li Y; Li Q; Mu L; Hu Y; Yan C; Zhao H; Mi Y; Li X; Tao D; Qin J
Int J Biol Sci; 2024; 20(7):2748-2762. PubMed ID: 38725859
[TBL] [Abstract] [Full Text] [Related]
2. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract] [Full Text] [Related]
3. The Human Intermediate Prolactin Receptor I-tail Contributes breast Oncogenesis by Targeting Ras/MAPK Pathway.
Shen S; Radhakrishnan SK; Harrell JC; Puchalapalli M; Koblinski J; Clevenger C
Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38713636
[TBL] [Abstract] [Full Text] [Related]
4. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
Ligumsky H; Amir S; Arbel Rubinstein T; Guion K; Scherf T; Karasik A; Wolf I; Rubinek T
Med Oncol; 2024 May; 41(6):138. PubMed ID: 38705935
[TBL] [Abstract] [Full Text] [Related]
5. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
6. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
7. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract] [Full Text] [Related]
8. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
9. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
[TBL] [Abstract] [Full Text] [Related]
10. Curcumin Inhibits the PPARδ-p-akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells.
Thulasiraman P; Foret M; Pandit R; McAlister K
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1035-1043. PubMed ID: 38546086
[TBL] [Abstract] [Full Text] [Related]
11. EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive breast cancer Cells.
Achounna AS; Ordaz-Rosado D; García-Quiroz J; Morales-Guadarrama G; Milo-Rocha E; Larrea F; Díaz L; García-Becerra R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542136
[TBL] [Abstract] [Full Text] [Related]
12. Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/PI3K/akt/NF-κB pathway.
Kim MJ; Lim SG; Cho DH; Lee JY; Suk K; Lee WH
Biochem Biophys Res Commun; 2024 May; 709():149828. PubMed ID: 38537596
[TBL] [Abstract] [Full Text] [Related]
13. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/akt/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
14. Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines.
Priyanka HP; Pratap UP; Nair RS; Vasantharekha R; ThyagaRajan S
Med Oncol; 2024 Mar; 41(5):92. PubMed ID: 38526769
[TBL] [Abstract] [Full Text] [Related]
15. Ropivacaine as a novel akt1 specific inhibitor regulates the stemness of breast cancer.
Ding L; Jiang H; Li Q; Li Q; Zhang TT; Shang L; Xie B; Zhu Y; Ding K; Shi X; Zhu T; Zhu Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):90. PubMed ID: 38523299
[TBL] [Abstract] [Full Text] [Related]
16. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
17. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
[TBL] [Abstract] [Full Text] [Related]
18. Uncovering the effect and mechanism of Jiawei Xiaoyao Wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis.
Bai Y; Niu L; Song L; Dai G; Zhang W; He B; San W; Li S
Phytomedicine; 2024 Jun; 128():155427. PubMed ID: 38513380
[TBL] [Abstract] [Full Text] [Related]
19. Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites.
Iwata M; Haraguchi R; Kitazawa R; Ito C; Ogawa K; Takada Y; Kitazawa S
J Cell Mol Med; 2024 Apr; 28(7):e18193. PubMed ID: 38506205
[TBL] [Abstract] [Full Text] [Related]
20. Synergy between PEDF and Doxorubicin in breast cancer Cells: Effects on Metastatic and Metabolic Pathways.
Abooshahab R; Al-Salami H; Dass CR
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474001
[TBL] [Abstract] [Full Text] [Related]
[Next]
